Atogepant
Calcitonin Gene-related Peptide Receptor Antagonist — NERVOUS SYSTEM
Also known as: AGN-241689, MK-8031, qulipta
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Atogepant is an onp drug in the Calcitonin Gene-related Peptide Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Calcitonin Gene-related Peptide Receptor Antagonists. DrugCentral lists 1 molecular target, including CALCRL. Recorded indications include Preventive treatment of episodic migraine in adults.
- Approval status: onp (first approved 2021 by the FDA).
- Drug class: Calcitonin Gene-related Peptide Receptor Antagonist.
- Mechanism of action: Calcitonin Gene-related Peptide Receptor Antagonists.
- Molecular targets: CALCRL (1 listed in DrugCentral).
- Indications: Preventive treatment of episodic migraine in adults.
- ATC code: N02CD07 (Calcitonin gene-related peptide (CGRP) antagonists).
- Molecular formula: C29H23F6N5O3; molecular weight 603.52 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Preventive treatment of episodic migraine in adults
Mechanism & targets
| Mechanism of action (MoA) | Calcitonin Gene-related Peptide Receptor Antagonists |
|---|---|
| Established pharmacologic class | Calcitonin Gene-related Peptide Receptor Antagonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Calcitonin gene-related peptide type 1 receptor | CALCRL | antagonist | Ki 10.82 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-08-11 | EMA | — | AbbVie Deutschland GmbH & Co. KG | |
| 2021-09-28 | FDA | — | ABBVIE INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N02CD07 | NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Constipation | 212.5 |
| Nausea | 121.8 |
| Migraine | 80.7 |
| Drug ineffective | 47.2 |
| Headache | 39.0 |
| Weight decreased | 37.8 |
| Therapeutic response shortened | 36.9 |
| Dizziness | 32.6 |
| Product administration interrupted | 29.5 |
| Therapy interrupted | 29.4 |
| Intentional dose omission | 29.3 |
| Surgery | 29.3 |
Chemical structure
| Molecular formula | C29H23F6N5O3 |
|---|---|
| Molecular weight | 603.52 g/mol |
| CAS number | 1374248-81-3 |
| InChIKey | QIVUCLWGARAQIO-OLIXTKCUSA-N |
| PubChem CID | 72163100 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Atogepant used for?
DrugCentral lists the following indications for Atogepant: Preventive treatment of episodic migraine in adults.
How does Atogepant work?
Atogepant is classified as Calcitonin Gene-related Peptide Receptor Antagonists; its molecular targets in DrugCentral include CALCRL (antagonist).
When was Atogepant first approved?
Atogepant was first approved by the FDA in 2021.
What drug class does Atogepant belong to?
Atogepant is in the Calcitonin Gene-related Peptide Receptor Antagonist class.
What is the chemical formula of Atogepant?
Atogepant has the molecular formula C29H23F6N5O3 and a molecular weight of 603.52 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5472 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3991065 — compound record and bioactivity
- PubChem CID 72163100 — chemical identifiers
- DrugBank DB16098 — drug record
- FDA UNII 7CRV8RR151 — substance identity
- DailyMed: FDA labels for Atogepant — current prescribing information (label search)
- UniProt Q16602 (CALCRL) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.